我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

慢性心力衰竭药物治疗的新希望—Entresto研究进展

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2018年第1期
页码:
1-004,012
栏目:
老年心血管病研究
出版日期:
2017-10-10

文章信息/Info

Title:
A new hope for heart failure treatment: development of Entresto research
作者:
侯莉明 综述; 王晓明 审校
(第四军医大学第一附属医院老年病科，陕西 西安 710032)
Author(s):
HOU Li-ming;  WANG Xiao-ming
(Department of Geriatrics, First Affiliated Hospital, Fourth Military Medical University, Xi’an 710032, Shaanxi, China)
关键词:
Entresto; 心力衰竭; 脑啡肽酶/血管紧张素受体双重抑制剂
Keywords:
entresto;  heart failure;  angiotensin receptor neprilysin inhibitor
分类号:
R541.6
DOI:
-
文献标识码:
A
摘要:
心力衰竭（heart failure，HF）简称心衰，是由各种原因所致心肌损伤最终导致心脏的心室泵血和（或）充盈能力下降的综合征，使静脉系统血液淤积，动脉系统血液灌注不足，从而引起心脏循环障碍症候群。HF具有患病率高，致死率高，医疗花费高等特点，呈现进行性发展、是严重危害着人类健康的一种疾病。然而，目前常规的HF治疗方法，无论是药物还是手术方式对患者获益仍十分有限。Entresto是新发现的一种具有脑啡肽酶/血管紧张素受体双重抑制效应的新型抗心衰药物，随着其上市应用与相关研究的报道，本文就其药效及药代学、临床研究及安全性等方面进行综述，为其合理应用于临床治疗HF提供更多研究依据。
Abstract:
Heart failure (HF), a myocardial injury syndrome with multiple etiologies, can result in reduction of ventricle pump function and/or filling ability with hypertension, coronary heart disease, and other cardiovascular pathogenesis. HF is a progressive disease, with high morbidity, a high fatality rate, and high associated medical costs. Unfortunately, at present, there are limited beneficial effects to current therupies. Entresto, which has dual effects on inhibition of both neprilysin and the rennin angiotensin aldosterone system, is a new type of drug utilized to treate HF. The present review aims to summarize pharmacodynamic/pharmacokinetics relationships, clinical efficacy, and the safety of Entresto. Finally, the review provides additional evidence for its clinical application.

参考文献/References

[1]Kobalava Z,Kotovskaya Y,Averkov O,et al.Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan(LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction[J].Cardiovasc Ther,2016,56(3):191-198.

[2]Ayalasomayajula SP,Langenickel TH,Jordaan P,et al.Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan),an angiotensin receptor neprilysin inhibitor[J].Eur J Clin Pharmacol,2016,72(9):1065-1073.

[3]Solomon SD,Zile M,Pieske B,et al.The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial[J].Lancet,2012,380(9851):1387-1395.

[4]McMurray JJ,Packer M,Desai AS,et al.Angiotensin-neprilysin inhibition versus enalapril in heart failure[J].N Engl J Med,2014,371(11):993-1004.

[5]Solomon SD,Claggett B,Desai AS,et al.Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan(LCZ696)in Heart Failure with Reduced Ejection Fraction The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure(PARADIGM-HF)Trial[J].Circ Heart Fail,2016,9(3):e002744.

[6]Kusaka H,Sueta D,Koibuchi N,et al.LCZ696,Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone[J].Am J Hypertens,2015,28(12):1409-1417.

[7]Ruilope LM,Dukat A,B?hm M,et al.Blood-pressure reduction with LCZ696,a novel dual-acting of the angiotensinII receptor and neprilysin:a randomised,double-blind, placebo-controlled,active comparator study[J].Lancet,2010,375(9722):1255-1266.

[8]Kario K,Sun N,Chiang FT,et al.Efficacy and Safety of LCZ696,a First-in-Class Angiotensi-n Receptor Neprilysin Inhibitor, in Asian Patients With Hypertension A Randomized,Double-Blind,Placebo-Controlled Study[J].Hypertension,2014,63(4):698-705.

[9]Izzo JJ,Zappe DH,Jia Y,et al.Efficacy and Safety of Crystalline Valsartan/Sacubitril(LCZ696)Compared With Placebo and Combinations of Free Valsartan and Sacubitril in Patients With Systolic Hypertension:The RATIO Study[J].Cardiovasc Pharmacol,2017,69(6):374-381.

[10]Bohm M,Young R,Jhund PS,et al.Systolic blood pressure, cardiovascular outcomes and efficacy and safety sacubitril/valsartan(LCZ696)in patients with chronic heart failure and reduced ejection fraction:results from PARADIGM-HF[J].Eur Heart J,2017,38(15):1132-1143.

[11]Hsiao HL,Langenickel TH,Petruck J,et al.Evaluation of pharmacokinetic and pharmacod-ynamic drug-drug interaction of sacubitril/valsartan(LCZ696)and sildenafil in patients withmild-to-moderate hypertension[J].Clin Pharmacol Ther,2017,17(1):558-559.

[12]Wang JG,Yukisada K,Sibulo AJr,et al.Efficacy and safety of sacubitril/valsartan(LCZ696)add on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy[J].Hypertens,2017,35(4):877-885.

[13]Supasyndh O,Sun N,Kario K,et al.Long-term(52-week)safety and efficacy of Sacubitril/v-alsartan in Asian patients with hypertension[J].Hypertens Res,2017,40(5):472-476.

[14]Voors AA,Gori M,Liu LC,et al.Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction[J].Eur J Heart Fail,2015,17(5): 510-517.

[15]Ito S,Satoh M,Tamaki Y,et al.Safety and efficacy of LCZ696,a first-in-class angiotens-in receptor neprilysin inhibitor,in Japanese patients with hypertension and renal dysfunction[J].Hypertens Res,2015,38(4):269-275.

[16]von Lueder TG,Wang BH,Kompa AR,et al. Angiotensin Receptor Neprilysin Inhibitor LCZ696 Attenuates Cardiac Remodeling and Dysfunction After Myocardial Infarction by Reducing Cardiac Fibrosis and Hypertrophy[J].Circ Heart Fail,2015,8(1):71-80.

[17]Bai HY,Mogi M,Nakaoka H,et al.Pre-treatment with LCZ696,an orally active angiotensin receptor neprilysin inhibitor,prevents ischemic brain damage[J].Eur J Pharmacol,2015,762(1): 293-298.

[18]Seferovic JP,Claggett B,Seidelmann SB,et al.Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes:a post-hoc analysis from the PARADIGM-HF trial[J].Lancet Diabetes Endo,2017,5(5):333-340.

[19]Malek V,Gaikwad AB.Neprilysin inhibitors: A new hope to halt the diabetic cardiovascular and renal complications?[J].Biomed Pharmacother,2017,90(1):752-759.

[20]Desai AS,Vardeny O,Claggett B,et al.Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsarta-n Compared With Enalapril:A Secondary Analysis of the PARADIGM-HF Trial[J].JAMA Cardiol,2017,2(1):79-85.

[21]B?hm M,Young R,Jhund PS,et al.Systolic blood pressure,cardiovascular outcomes and ef-ficacy and safety of sacubitril/valsartan(LCZ696)in patients with chronic heart failure andreduced ejection fraction:results from PARADIGM-HF[J].Eur Heart J,2017,38(15):1132- 1143.

[22]Vodovar N,Paquet C,Mebazss A,et al.Neprilysin,cardiovascular,and Alzheimer’s disease:the therapeutic spilt[J].Eur Heart J,2015,36(15):902-905.

[23]Langenickel TH,Tsubouchi C,Ayalasomayajula S,et al.The effect of LCZ696(sacubitril/va-lsartan)on amyloid-β concentrations in cerebrospinal fluid in healthy subjects[J].Brit J Cli-n Pharmaco,2016,81(5):878-890.

[24]Schoenfeld HA,West T,Verghese PB,et al.The effect of angiotensin receptor neprilysin inhibitor,sacubitril/valsartan,on central nervous system amyloid-βconcentrations and clearance in the cynomolgus monkey[J].Toxicol Appl Pharmacol,2017,323(1):53-65.

[25]Kulmatycki KM,Langenickel T,Ng WH,et al.Pharmacokinetics and safety of sacubitril/val-sartan(LCZ696)in patients with mild and moderate hepatic impairment[J].Int J Clin Pharmacol Ther,2017,55(9):728-739.

[26]van der Pol S,Degener F,Postma MJ,et al.An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands[J].Value in Health,2017,20(3):388-396.

备注/Memo

备注/Memo:
收稿日期：2017-08-21.基金项目：国家自然科学基金项目资助（81270169） 通讯作者：王晓明，主任医师，主要从事心血管疾病基础与临床研究 Email:xmwang@fmmu.edu.cn 作者简介：侯莉明，硕士生 Email：13319189560@163.com
更新日期/Last Update: 1900-01-01